DYSLIPIDEMIA IN CHRONIC KIDNEY DISEASE

被引:0
|
作者
Singh, Manish Kumar [1 ]
Charan, V. D. [1 ]
Parasher, Ishan [2 ]
Pankaj, Pranjal [1 ]
Kumar, Shrawan [1 ]
Gupta, Kusum [1 ]
Singh, Vindhyawasini Prasad [1 ]
机构
[1] Rama Med Coll Hosp & Res Ctr, Dept Med, Kanpur, Uttar Pradesh, India
[2] Rama Med Coll Hosp & Res Ctr, Dept Biochem, Kanpur, Uttar Pradesh, India
关键词
Chronic kidney disease; dyslipidemia; Cholesterol; LDL; HDL; VLDL;
D O I
10.14260/jemds/1224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Chronic kidney disease encompasses a spectrum of different pathophysiological processes associated with abnormal kidney function and a progressive decline in glomerular filtration rate (GFR). Chronic kidney disease is a universal medical problem across the globe. Unless treated, it may lead to grave consequences. Chronic kidney disease leads to impairment of excretory, metabolic and endocrine functions of the kidney. As other complications of CKD occur, likewise it also results in profound lipid disorders In view of the effect of dyslipidemia on cardiovascular risk and possibly on the progression of renal disease, treatment seems sensible, although evidence is not abundant. AIMS AND OBJECTIVES: 1. Study the lipid profile in the cases of chronic kidney disease. 2. Study the significance of dyslipidemia in chronic kidney disease. MATERIAL AND METHODS: The study was carried out in a group of patients who were admitted and patients visiting the outpatient department of the Department of Medicine at Rama Medical College, Kanpur, Patients were selected by adhering strictly to certain inclusion (Patients of chronic kidney disease on conservative treatment and on haemodialysis or peritoneal dialysis) and exclusion criteria (renal failure other than CKD or on hypolipidemic drugs). RESULTS: In our study 30% of the cases, the cholesterol value is within normal limits. 18% cases its level is high i. e. above 240 and in rest 52 % of cases it is within the borderline high range. The mean triglyceride is 218.74 mg/dl in patients of CKD and is 87.04 mg/dl in control subjects which is statistically very significant. The mean VLDL is 43.78 mg/dl in patients of CKD and is 17.41 mg/dl in control subjects which is statistically very significant. 90% cases had HDL < 40 mg/dl. 6% of the patients had serum LDL value within normal range. 32% of the patients had optimal serum LDL cholesterol value near or above normal range. 36 % of the patient had serum LDL value in borderline high range. 12% of the patient had serum LDL cholesterol value in high range. 14% of the patient had serum LDL cholesterol value in very high range. The mean LDL/HDL ratio is 4.44 in patients of CKD and is 2.66 in control subjects. The mean TG/HDL ratio is 7.02 in patients of CKD and is 1.88 in control subjects. Mean TG/LDL ratio is 1.66 in patients of CKD and is 0.71 in control subjects. CONCLUSION: In the cases of chronic kidney disease there is dyslipidemia with maximum impact on level of triglycerides with a very significant increase. The level of total cholesterol is increased, that of HDL is decreased and level of VLDL is increased. These changes are occurring independently in chronic kidney disease.
引用
收藏
页码:6864 / 6875
页数:12
相关论文
共 50 条
  • [41] A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease
    Abe, Masanori
    Maruyama, Noriaki
    Maruyama, Takashi
    Okada, Kazuyoshi
    Soma, Masayoshi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2015, 22 (12) : 1235 - 1247
  • [42] At which stage of chronic kidney disease should dyslipidemia be treated?
    Vera Krane
    Christoph Wanner
    Nature Clinical Practice Nephrology, 2006, 2 : 176 - 177
  • [43] The research of the association between dyslipidemia and chronic kidney disease.
    Li, Xia
    Chen, Yintao
    Chen, Shuang
    Sun, Guozhe
    Sun, Yingxian
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (18): : 7800 - 7805
  • [44] Dyslipidemia in chronic kidney disease and end-stage renal disease: A review
    Appel, GB
    Appel, AS
    DIALYSIS & TRANSPLANTATION, 2004, 33 (11) : 714 - +
  • [45] The effects of chronic kidney disease stages on dyslipidemia, cardiovascular disease prevalence and mortality
    Hoca, Emre
    Mermer, Huseyin Bulent
    Kula, Atay Can
    Ahbab, Suleyman
    Ataoglu, Hayriye Esra
    NORTHERN CLINICS OF ISTANBUL, 2025, 12 (01) : 95 - 102
  • [46] Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
    Theofilis, Panagiotis
    Vordoni, Aikaterini
    Koukoulaki, Maria
    Vlachopanos, Georgios
    Kalaitzidis, Rigas G.
    AMERICAN JOURNAL OF NEPHROLOGY, 2021, 52 (09) : 693 - 701
  • [47] Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk
    Theofilis, Panagiotis
    Vlachakis, Panayotis K.
    Karakasis, Paschalis
    Kalaitzidis, Rigas G.
    CURRENT ATHEROSCLEROSIS REPORTS, 2025, 27 (01)
  • [48] Valvular and vascular calcifications in patients with chronic kidney disease: The role of dyslipidemia
    Bijak, Krzysztof
    Matuszkiewicz-Rowinska, Joanna
    Niemczyk, Stanislaw
    Wlodarczyk, Dariusz
    Przedlacki, Jerzy
    Trebicka, Jadwiga
    Ostrowski, Kazimierz
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 404 - 405
  • [49] Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease
    Holzmann, Martin J.
    Jungner, Ingmar
    Walldius, Goran
    Ivert, Torbjorn
    Nordqvist, Tobias
    Ostergren, Jan
    Hammar, Niklas
    ANNALS OF MEDICINE, 2012, 44 (03) : 262 - 270
  • [50] Dyslipidemia in Chronic Kidney Disease: Managing a High-Risk Combination
    Chauhan, Veeraish
    Vaid, Megha
    POSTGRADUATE MEDICINE, 2009, 121 (06) : 54 - 61